FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912394042> ?p ?o ?g. }

• W2912394042 abstract "Introduction Secondary hyperparathyroidism is one of the common hormonal complication of chronic kidney disease. There are several therapeutic options for management of sHPT aiming at normalization of calcium-phosphorus balance and decrease of parathyroid hormone secretion. Objectives The aim of this retrospective, observational study was to assess the outcome of three most common therapeutic strategies of secondary hyperparathyroidism treatment with vitamin D receptor activator-paricalcitol, calcimimetic-cinacalcet or both agents administered together during in 12-months period. Methods 131 haemodialysed patients with uncontrolled parathyroid hormone secretion has been treated with intravenous paricalcitol (60 patients) or oral cinacalcet (50 patients). The third group (21 patients) received intravenous paricalcitol and oral cinacalcet administered simultaneously. Results In all groups, a significant decrease of iPTH level was observed, however in group treated with intravenous paricalcitol iPTH level decreased significantly higher than in group treated with cinacalcet and in the third one treated with paricalcitol and cinacalcet in parallel. The highest change of iPTH level was noticed after three months of observation. After this period the iPTH level was stabilized and remained on similar level till the end of observation. The level of safety is similar for all the strategies. No severe hypercalcemia or hypocalcemia was observed during the whole period of observation. Conclusions The results of this study show significant advantage of intravenous treatment with paricalcitol. Adding paricalcitol to the therapy with cinacalcet does not improve the outcomes of the treatment. In case of unsatisfactory results after the 3-months treatment, a possible continuation should be considered carefully. Treatment with intravenous paricalcitol should be considered in all haemodialysed patients with inadequate control of serum PTH level. sHPT treatment with cinacalcet should be considered in PD patients and when severe hypercalcemia occurs." @default.
• W2912394042 created "2019-02-21" @default.
• W2912394042 creator A5015815038 @default.
• W2912394042 creator A5028627521 @default.
• W2912394042 creator A5042539798 @default.
• W2912394042 creator A5075740190 @default.
• W2912394042 creator A5085600917 @default.
• W2912394042 creator A5088466358 @default.
• W2912394042 date "2019-02-05" @default.
• W2912394042 modified "2023-09-27" @default.
• W2912394042 title "Three Therapeutic Strategies: Cinacalcet, Paricalcitol or Both in Secondary Hyperparathyroidism Treatment in Hemodialysed Patients During 1-Year Observational Study—A Comparison" @default.
• W2912394042 cites W1768768381 @default.
• W2912394042 cites W1963611706 @default.
• W2912394042 cites W1966916284 @default.
• W2912394042 cites W1973835767 @default.
• W2912394042 cites W1997100043 @default.
• W2912394042 cites W2007947358 @default.
• W2912394042 cites W2017729196 @default.
• W2912394042 cites W2026395289 @default.
• W2912394042 cites W2027414087 @default.
• W2912394042 cites W2028875889 @default.
• W2912394042 cites W2041692221 @default.
• W2912394042 cites W2045929055 @default.
• W2912394042 cites W2054323843 @default.
• W2912394042 cites W2065408489 @default.
• W2912394042 cites W2073753543 @default.
• W2912394042 cites W2095527531 @default.
• W2912394042 cites W2109064733 @default.
• W2912394042 cites W2110553860 @default.
• W2912394042 cites W2114902110 @default.
• W2912394042 cites W2114962014 @default.
• W2912394042 cites W2119569261 @default.
• W2912394042 cites W2121613126 @default.
• W2912394042 cites W2121733531 @default.
• W2912394042 cites W2129578672 @default.
• W2912394042 cites W2132079584 @default.
• W2912394042 cites W2133560366 @default.
• W2912394042 cites W2136486000 @default.
• W2912394042 cites W2143168714 @default.
• W2912394042 cites W2143470199 @default.
• W2912394042 cites W2143664225 @default.
• W2912394042 cites W2144627797 @default.
• W2912394042 cites W2153509237 @default.
• W2912394042 cites W2154154851 @default.
• W2912394042 cites W2160374584 @default.
• W2912394042 cites W2162714394 @default.
• W2912394042 cites W2163719021 @default.
• W2912394042 cites W2401129071 @default.
• W2912394042 cites W2475261460 @default.
• W2912394042 cites W2523744778 @default.
• W2912394042 cites W2560519247 @default.
• W2912394042 cites W2751533291 @default.
• W2912394042 cites W2767174426 @default.
• W2912394042 cites W4234582290 @default.
• W2912394042 cites W4237871677 @default.
• W2912394042 doi "https://doi.org/10.3389/fendo.2019.00040" @default.
• W2912394042 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6371033" @default.
• W2912394042 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30804890" @default.
• W2912394042 hasPublicationYear "2019" @default.
• W2912394042 type Work @default.
• W2912394042 sameAs 2912394042 @default.
• W2912394042 citedByCount "6" @default.
• W2912394042 countsByYear W29123940422020 @default.
• W2912394042 countsByYear W29123940422021 @default.
• W2912394042 countsByYear W29123940422023 @default.
• W2912394042 crossrefType "journal-article" @default.
• W2912394042 hasAuthorship W2912394042A5015815038 @default.
• W2912394042 hasAuthorship W2912394042A5028627521 @default.
• W2912394042 hasAuthorship W2912394042A5042539798 @default.
• W2912394042 hasAuthorship W2912394042A5075740190 @default.
• W2912394042 hasAuthorship W2912394042A5085600917 @default.
• W2912394042 hasAuthorship W2912394042A5088466358 @default.
• W2912394042 hasBestOaLocation W29123940421 @default.
• W2912394042 hasConcept C124490489 @default.
• W2912394042 hasConcept C126322002 @default.
• W2912394042 hasConcept C126894567 @default.
• W2912394042 hasConcept C134018914 @default.
• W2912394042 hasConcept C2775945674 @default.
• W2912394042 hasConcept C2776036575 @default.
• W2912394042 hasConcept C2777425297 @default.
• W2912394042 hasConcept C2778653478 @default.
• W2912394042 hasConcept C2778838027 @default.
• W2912394042 hasConcept C2779524405 @default.
• W2912394042 hasConcept C2780280601 @default.
• W2912394042 hasConcept C2780534505 @default.
• W2912394042 hasConcept C2781208988 @default.
• W2912394042 hasConcept C519063684 @default.
• W2912394042 hasConcept C71924100 @default.
• W2912394042 hasConceptScore W2912394042C124490489 @default.
• W2912394042 hasConceptScore W2912394042C126322002 @default.
• W2912394042 hasConceptScore W2912394042C126894567 @default.
• W2912394042 hasConceptScore W2912394042C134018914 @default.
• W2912394042 hasConceptScore W2912394042C2775945674 @default.
• W2912394042 hasConceptScore W2912394042C2776036575 @default.
• W2912394042 hasConceptScore W2912394042C2777425297 @default.
• W2912394042 hasConceptScore W2912394042C2778653478 @default.
• W2912394042 hasConceptScore W2912394042C2778838027 @default.
• W2912394042 hasConceptScore W2912394042C2779524405 @default.
• W2912394042 hasConceptScore W2912394042C2780280601 @default.
• W2912394042 hasConceptScore W2912394042C2780534505 @default.

• next